Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high... see more

TSX:SZLS - Post Discussion

StageZero Life Sciences Ltd > 3/31 cash on hand was $6.4M - only going up from here
View:
Post by 2021Gamble on May 17, 2021 9:18pm

3/31 cash on hand was $6.4M - only going up from here

Q1 Revenue of $2.5 Million

TORONTO, ON / ACCESSWIRE / May 17, 2021 / StageZero Life Sciences, Ltd. (TSX:SZLS) ("StageZero" or the "Company"), a specialist in PCR testing dedicated to the early detection of multiple diseases through whole blood, today announced its first-quarter financial results for the three months ended March 31, 2021, and provided an update on its business progress.

The Company generated $2.5M in revenue from COVID testing for the quarter. Net loss for the quarter totaled $7.3M. To reflect the operations of the Company more clearly, management has prepared an analysis of EBITDA and Adjusted EBITDA in the MD&A. As disclosed in the MD&A, the adjusted EBITDA for the quarter was $193,000. As at March 31, 2021, the Company had $6.4 million in cash.

Comment by kodiakup on May 17, 2021 10:15pm
- something is wrong....  - Loss of 0.08 / per share and loss of 7.3 million in the last quarter ... but they made a turnover of 2.5 million .......weird..... - 6.4 million in bank ouffff proved me ... Total assets 8,234,028 - Total current liabilities 6,135,175 = 2 millions of values 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities